Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 2/20 | 0.38 |
| ▸ | MMP13 | P45452 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6443671 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2PLA2G2APLA2G5TYRPPARG | |
| SCHEMBL1287155 | 0.89 | SMN1; SMN2 (0.53) | SMN1; SMN2PLA2G2APLA2G5TYRPPARG | |
| SCHEMBL7755148 | 0.89 | SMN1; SMN2 (0.53) | SMN1; SMN2PLA2G2APLA2G5TYRPPARG | |
| SCHEMBL509967 | 0.89 | SMN1; SMN2 (0.53) | SMN1; SMN2PLA2G2APLA2G5TYRPPARG | |
| SCHEMBL8466581 | 0.88 | SMN1; SMN2 (0.55) | SMN1; SMN2PLA2G2APLA2G5PPARGPPARA | |
| SCHEMBL9828390 | 0.88 | SMN1; SMN2 (0.55) | SMN1; SMN2PLA2G2APLA2G5PPARGPPARA | |
| SCHEMBL8467616 | 0.88 | SMN1; SMN2 (0.55) | SMN1; SMN2PLA2G2APLA2G5PPARGPPARA | |
| SCHEMBL7769533 | 0.86 | PLA2G2A (0.56) | SMN1; SMN2PLA2G2APLA2G5PPARGPPARA | |
| SCHEMBL7770755 | 0.86 | PLA2G2A (0.56) | SMN1; SMN2PLA2G2APLA2G5PPARGPPARA | |
| SCHEMBL7770760 | 0.86 | PLA2G2A (0.56) | SMN1; SMN2PLA2G2APLA2G5PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| US-5491165-A | Fungicidal active compound combinations | BAYER AKTIENGESELLSCHAFT (DE) | 1996-02-13 | — | — | US | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | SMN1; SMN2 1200/4885PLA2G2A 2270/4885PLA2G5 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.